Compare Tractor Supply Co (TSCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tractor Supply Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Tractor Supply Co trades at $34 (market cap $18.39B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× Tractor Supply Co's market cap, and Tractor Supply Co pays a 2.72% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TSCO | VRTX | |
|---|---|---|
Market Cap | $18.39B | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $60.61 | $557.96 |
52-Week Low | $29.14 | $376.62 |
Enterprise Value | $24.70B | $128.18B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tractor Supply Company (TSCO) trades at $35.29, up 0.86% on the day, with a bullish technical signal from moving averages. The stock is supported by strong profitability, including a 39.51% ROE and 6.42% net income margin, though recent quarterly EPS results have missed expectations. Revenue growth remains steady, reaching $15.52B in 2025, while analyst consensus is a Buy with a $36.29 price target. Recent corporate developments include a dividend payment and participation in industry conferences.
The outlook for TSCO is cautiously optimistic, with upside potential near the consensus target, but risks include competitive pressures and cyclical sales headwinds. Investment appeal hinges on execution of strategic initiatives in pet care and logistics, while monitoring margin trends and same-store sales performance is critical for sustained growth.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
